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CHAPTER 1 INTRODUCTION
1.1 INTRODUCTION TO DIABETES AND INSULIN SIGNALING PATHWAY
1.1.1 INTRODUCTION TO DIABETES
Diabetes is a metabolic disorder characterized by high blood glucose. According to the National diabetes statistics report, by 2012, 29.1 million of the U.S population
had diabetes. Out of which 21 million are diagnosed and 8.1 million undiagnosed. 1.7
million New cases of diabetes have been diagnosed in 2012. 86 million aged 20 or older
had pre-diabetes in 2012 compared to 79 million in 2010 which went high by 7 million.
In 2010, it was the 7th leading cause of death. There are many complications associated
with diabetes besides high blood glucose levels. Eventually, they can have impaired
functioning of heart, kidneys, nerves, eyes and blood vessels. These people have higher
risk for stroke and heart disease1. Neuropathy (nerve damage) is other common effect.
This increases the incidence of foot ulcers, infections and also can lead to limb amputations. Diabetic retinopathy associated blindness accounts for 1% of the global blindness2. Diabetes can also lead to kidney failure3.
There are two major types of diabetes: type I and type II. Type II Diabetes
accounts for 90-95% of all diabetic cases. Type I Diabetes is seen in children and young
adults due to the lack of insulin production caused by the loss of pancreatic beta cells.
This is also called insulin dependent diabetes mellitus. Type II Diabetes occurs in relatively older people, which is the consequence of a combination of insulin resistance and
relative insulin deficiency4.
Insulin is a hormone produced by the islet cells in response to the rise in blood
glucose levels4. More than 70% of insulin-stimulated glucose uptake takes place in
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skeletal muscle. Insulin resistance in skeletal muscle is one of the major defects in Type
II diabetes4.
1.1.2 INSULIN SIGNALING PATHWAYS
Insulin increases glucose uptake, synthesis of proteins, lipids and glycogen
through activation of various pathways in skeletal muscle cells. Insulin binds to the
insulin receptor, a tyrosine kinase receptor, causes the activation of the receptor that
triggers cascades of events. The various substrates for the insulin receptor include insulin receptor substrate 1 (IRS1), P60, Gab-1, cbl and Isoforms of shc. The phosphorylated tyrosines on these substrates allow them to bind to various downstream molecules, which include P85 subunit of the phosphatidylinositide 3 kinase (PI3K), Grb2,
crk II, etc. PI3K binds to IRS1, which activates Akt to enhance GLUT4 translocation
and thereby glucose uptake, glycogen synthesis, and protein synthesis. Insulin also
activates mitogen-activated protein kinases (MAPK) to increase gene expression and
differentiation5.

1.2 KINASES AND PHOSPHATASES
Phosphorylation is one of the most important post translational modifications
which regulates most signaling molecules in the cell. This process is carried out by
kinases contrary to the phosphatases which carry out dephosphorylation. Of all the proteins in the eukaryotic cell, one third portions undergo reversible phosphorylation6.
Phosphatases remove phosphate group by nucleophilic attack in the presence of water.
Phosphorylation and dephosphorylation are mostly carried out on amino acids containing OH group such as serine, threonine and tyrosine. Among these, serine undergoes
almost 86.4% of the total phosphorylation followed by threonine (11.8%) and tyrosine
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(1.8%)7. Kinases are classified as protein tyrosine kinases and serine/threonine kinases.
Characterization of phosphatases is based on their substrates:
i.

Protein Tyrosine Phosphatases (PTP): remove the phosphate group from
phosphorylated tyrosine residues.

ii.

Protein Serine/Threonine Phosphatases: remove the phosphate group from
phosphorylated serine/threonine residues. This group is Further classified
into Phospho Protein Phosphatase (PPP) which includes PP1, PP2A, PP2B,
PP4, PP5, PP6, PP7 and Metal ion (Mg+2 and Mn+2) dependent phosphatase
(PPM) which includes PP2C.

iii.

Dual specificity protein serine/threonine/tyrosine phosphatase.

iv.

Histidine phosphatase

v.

Lipid phosphatase.
As their names suggest, their substrates involve phosphorylated tyrosine, ser-

ine/threonine, serine/threonine/tyrosine, or histidine residues and lipids, respectively.
The number of genes coding kinases approximately 3 fold higher than that of
phosphatases8. Balancing the large number of kinases is achieved by the presence of
various isoforms of each subunit composing the phosphatases. Phosphatases are complexes, generally composed of a catalytic subunit and one or more regulatory subunits.
The catalytic subunit itself is relatively non-specific and can dephosphorylate numerous
substrates. Therefore, the interaction between the catalytic subunit and regulator subunits is required to regulate the specificity and activity of the phosphatases8.
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1.3 PROTEIN PHOSPHATASE 2A (PP2A), REGULATION AND EFFECT OF
INSULIN

PP2A is a one of the major serine-threonine protein phosphatase that belongs to
the phosphoprotein phosphatase family. This phosphatase constitutes for about 1% of
the total protein in the cell9. It is a hetero trimeric complex with a dimeric core enzyme
(see Figure 2), composed of a 65kda A subunit (PP2Aa), a 55kda B regulatory subunit
(PP2Ab), and a 36kda catalytic subunit C (PP2Ac). Subunits A and C form the dimeric
core10.
1.3.1 SUBUNITS OF PP2A
PP2Aa (A regulatory subunit) is ubiquitous and has two isoforms, alpha and
beta, which are encoded by two different genes PPP2R1A and PPP2R1B. There is 86%
similarity between these two isoforms. The dimer core, in most cases (90%), is composed of A alpha isoform9. Both the isoforms are located in the cytoplasm. It is composed of 15 non-identical repeats (HEAT sequence) containing 39 amino acids each.
The repeats contain two alpha helices which are connected to each other by intra and
inter repeat loops forming a horse-shoe shape. B subunit binds to loops 1-10 whereas
C subunit binds to loops 11-1511. Because of its flexibility, B subunits and other substrates can be incorporated easily9. PP2Aa guides PP2Ac in the interaction with PP2Ab
and other substrates and regulates the specificity of PP2Ac12.
PP2Ab (B regulatory subunit) regulates localization, activity and substrates for
the complex. This regulatory subunit is encoded by 15 different genes which are transcribed to a minimum of 26 transcripts and splice variants. They are expressed variably
depending on the tissue type. They are classified as B (B55/PR55), B’ (B56/PR61), B‘’
(PR48/PR72/PR130), and B‘’’ (PR93/PR110). They require ATP and Mg+2 to be active.
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B has four different isoforms and has a tryptophan-aspartate repeat which helps in its
identification. B’ has five isoforms which are all identical in the center region but different in the C and N terminals. B’’ has three isoforms. Different regulatory subunits
direct the holoenzyme to perform varied functions. For example, binding of B subunit
to the PP2A complex prevents simian virus40 replication whereas binding of B’’ does
the opposite.
PP2Ac (catalytic subunit) is in globular structure, ubiquitously expressed in almost all the tissues and is abundant in heart and brain. PP2Ac is conserved from eukaryotes to mammals, with 86% sequence match between yeast and humans. It is responsible for the catalytic activity of the enzyme. PP2Ac has two isoforms, alpha and beta,
which are 97% identical. Both are composed of 309 amino acids and differ only by 8
amino acids at the N terminal. PP2Ac alpha is found mainly in plasma membrane
whereas beta isoform is in cytoplasm and nucleus. PP2Ac alpha is more abundant than
PP2Ac beta because of the high degree of mRNA translation13. Unique feature of
PP2Ac is that C terminal tail is highly conserved (304TPDYEL309). This tail binds to the
A and B subunits of the complex.
1.3.2 REGULATION OF PP2A
Given the presence of large number of A, B and C subunit isoforms, various
PP2A complexes are possible. The combination of the A, B and C subunit isoforms
affects the activity and specificity of PP2A complexes against a particular substrate.
Binding and the presence of other regulators can also influence PP2A activity and specificity14,15.
PP2A activity is also regulated by post-translational modifications16. Several
experiments in vivo as well as in vitro showed that phosphorylation on Tyr307 on
PP2Ac16 deactivates PP2Ac by preventing its interaction with the regulatory subunit.
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Phosphorylation is also reported in a few PP2A regulatory subunits, which altered their
activity and also substrate specificity. In addition, carboxyl methylation on the carboxyl group of the C-terminal residue of Leu309 increases the activity of PP2Ac by increasing its binding to A and B subunits. Leucine Carboxyl Methyl Transferase
(LCMT), also known as PP2A-Methyl transferase (PPMT), is responsible for methylation of PP2Ac, while PP2A Methyl Esterase (PPME) is responsible for PP2Ac de-methylation.
1.3.3 INHIBITORS OF PP2A
There are two inhibitors which are found to inhibit PP2A which are found
through in vitro and in vivo experiments which are termed as I1PP2A and I2PP2A 16. Many
small compound found naturally inhibit PP2A. One of them being Okadaic acid which
is being used in laboratory practices. It also inhibits other phosphatases like pp1 but at
relatively higher concentrations. Other commercially available inhibitors include calyculin a, tautomycin, microcystins, cantharidin and endothall.
1.3.4 ROLE OF PP2A
PP2A is found to be involved in many cell signaling pathways, cell cycle regulation and various other pathways. Experiments conducted by employing phosphatase
inhibitor Okadaic acid showed that PP2A plays a role in cell cycle regulation (G2/M
transition). Using Yeast, they presented the role of various B subunit analogues in cell
cycle, stress response, cytoskeleton organization and morphogenesis. Experiments on
drosophila showed the importance of PP2A in early embryogenesis and the changes in
the tissue distribution during its development. Several viral antigens are found to interact with PP2A and prevent the inhibitory role of PP2A in those signaling pathways and
promote cell proliferation. It is also shown in Xenopus eggs that it involves in initiation
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of DNA replication. Several experiments showed the involvement of PP2A in termination of DNA replication, apoptosis, DNA damage response and heat shock response13.
1.3.5 PP2A IN INSULIN SIGNALING
Saturated fatty acids like palmitate negatively regulate insulin signaling pathway
by activating PP2A, which dephosphorylates Akt and ERK1/2. Opposite effect is seen
with unsaturated fatty acids like oleic acid or linoleic acid17.
There are evidences that insulin inactivates PP2A through in vitro and in vivo
experiments. Also published evidence shows interaction of PP2A with many signaling
molecules, some of which are involved in insulin signaling pathway. Jian Chen et al
showed that PP2A is phosphorylated in vitro by the tyrosine kinases which included
insulin receptors. It is phosphorylated on Tyr307 and this inactivated PP2A16 .
The effect of insulin on PP2A during myogenesis in rat L6 cells is shown by
Srinivasan and Begum. They showed that insulin inactivated PP2A in the differentiated
cells .They also showed that the phosphatase activity decreased relatively with the increased concentrations of insulin and also the incubation time18.
One of the effects of insulin in skeletal muscle cells is the glycogen synthesis
through the INS/IRS-1/pkb pathway. Rosanna Cazzolli and associates showed that
ceramide treatment of C2C12 skeletal myotubes reduced the glycogen synthesis
through inhibition of phosphorylation on PKB upon insulin stimulation. They proved
that this inhibition is mediated through activated PP2A via ceramide and thereby effecting the glycogen synthesis in the skeletal muscle cells19.
It is also shown that PP2A has a positive effect on the INS signaling pathway
by preventing the excessive serine phosphorylation on the IRS-1 which will otherwise
negatively regulate the pathway. One such serine kinases is ribosomal protein P70 S6K1 which is an effector of mTOR. They showed direct Interaction of PP2A with IRS-1
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in cardiomyocytes protecting IRS-1 from excessive serine phosphorylation. They inferred from their results that PP2A interacts with IRS-1 via mTOR competing for serine
residues on IRS-1 and thereby deciding the phosphorylation status of IRS-1. Many factors affect the association, one being the INS stimulation20.
Only one group conducted experiments on human skeletal muscle where they
compared ten type II diabetics with ten controls. They showed that upon insulin stimulation, PP2A levels in control subjects reduced when compared to the basal levels but
not in type II diabetics. They also showed corresponding reduction in glucose disposal,
glucose oxidation and increase in lipid oxidation21.

1.4 INSULIN SENSITIVITY; PROTEIN INTERACTIONS AND MASS SPECTROMETRY

1.4.1 METHODS TO MEASURE INSULIN SENSITIVITY
There are several methods to measure insulin sensitivity in humans. Hyperinsulinemic euglycemic clamp and insulin suppression test are used for direct measurement
of insulin sensitivity whereas Oral glucose tolerance test and minimal model analysis
of frequently sampled intravenous glucose tolerance test are considered for indirect
measurement. There are several other Indices used for quick measurement of insulin
sensitivity in cases where feasibility is an issue.22
For settings where insulin sensitivity measurement and maintenance of steady
state conditions is crucial, hyperinsulinemic euglycemic clamp should be the first
choice. This technique is also mentioned as a gold standard to assess the action of insulin in vivo23. The action of insulin on the body is measured by the rate of exogenous
glucose infused to maintain a constant blood glucose concentration. Under conditions
of hyperinsulinemia, most (>70%) of the infused glucose is used by skeletal muscle.
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This implies that the index measured during the clamp mainly reflects the skeletal muscle sensitivity to insulin4.
1.4.2 IMPORTANCE OF PROTEIN-PROTEIN INTERACTIONS
Most of the proteins in vivo act in the form of complexes. These proteins contribute to about 80%. Protein interactions play a very crucial role in various functions
of the cell, such as gene transcription, signal transduction24, cell cycle regulation, etc.
Correct formation of these complexes is important for the normal body function. Abnormalities in protein-protein interactions cause aberrant cell signals and thereby cause
diseases. Many protein complexes have been targeted to treat diseases25. Studying the
interactions will help us to find out the function of the particular target protein which is
specifically useful in cases of any unidentified protein. It will also enable us to analyze
the signaling pathways. Protein-protein Interactions have been classified as homo oligomeric /hetero oligomeric based on interaction surface; obligate/non obligate based
on stability and transient/permanent depending on persistence26
Protein-protein interactions may result in changes in
1. Kinetic characteristics of the complexes
2. Substrate channeling
3. A new binding site on the complex for other effector molecules
4. Substrate specificity
5. Activity of the complex
6. Downstream events
Methods to determine protein-protein interactions. Biophysical methods determine these interactions using the structural information of the proteins. These include
X-ray crystallography, NMR Spectroscopy, fluorescence and atomic force microscopy.
Direct high throughput methods include yeast two hybrid, affinity purification and mass
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spectrometry27,28,29. Indirect high throughput methods include gene co-expression and
synthetic lethality. Computational predictions of the protein-protein interactions have
also been reported27. Affinity purification coupled with mass spectrometry (AP-MS) is
widely used for identification of interaction networks28. Affinity purification allows to
enrich the target protein of interest and its co-interaction partners in a single step, and
mass spectrometry offers supreme ability to identify proteins from a complex mixture
in a high throughout fashion28,29.

1.4.3 MASS SPECTROMETRY
Mass spectrometry is the most sensitive approach for global identification and
quantification of proteins, protein-protein interactions, and protein post translational
modifications30. The main components of a mass spectrometry instruments, a mass
spectrometer, include an ion source, a mass analyzer, and a detector30:
1. Ion source: a device to generate charged particles. Electrospray ionization
(ESI) and matrix-assisted laser desorption ionization (MALDI) are two commonly used ion sources for proteomics studies30.
2. Mass analyzer: a device to separate the ions based on their mass-to-charge
ratio, m/z30. Four common types of analyzers for the proteomic analysis include
quadruple, Ion trap (quadruple ion trap, linear ion trap), time of flight, and orbitrap analyzers30.
3. Detector: A detector is a device to record either the charge induced when an
ion hits a surface or the current produced when an ion passes by 30. Two main
detectors are electron multiplier (charge induced when ions hit a plate) and image current detector (current produced when ions pass) 30.
As every wet lab experiment, proteomics studies begin with collecting starting
material (e.g., tissue, body fluid, cell lysates, etc.) and followed by protein separation

11

(e.g., affinity capture, electrophoresis, liquid chromatography, etc.).

Proteins are

cleaved into peptides by enzymatic digestion. The most commonly used protease/enzyme for this purpose is trypsin due to its well defined specificity, which hydrolyzes
proteins at the carboxyl side (or "C-terminal side") of the amino acids lysine and arginine. Since one protein may generate many peptides after trypsin digestion, a tryptic
digest of a complex mixture of proteins may contain thousands or even millions of
peptides. Therefore, the resulting peptides are further separated using a variety of techniques (e.g. affinity capture, liquid chromatography, etc.). The separated peptides are
analyzed by mass spectrometry for peptide/protein identification and quantification.
In the present work, the proteomic approach developed in our laboratory31 was
applied to investigate PP2Ac interaction partners in human skeletal muscle from overweight/obese non-diabetic human participants. I asked following three questions 1).
Are PP2Ac interaction partners reported in cell culture or animal models indeed interact
with PP2Ac in human skeletal muscle? 2). Are there new PP2Ac interaction partners in
human skeletal muscle? 3). Are there insulin responsive PP2Ac interaction partners in
human skeletal muscle?
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CHAPTER 2 RESEARCH DESIGN AND METHODS
Clinical and proteomics studies were carried out similar to those describe31,
which reported the discovery of new IRS1 interaction partners in human skeletal muscle. The main difference was that PP2Ac Co-immunoprecipitation was used to enrich
PP2Ac interaction partners in the present work instead of IRS1 Co-immunoprecipitation used in the publication.
As illustrated in Fig. 3, the approach we used included extensive clinical and
proteomics data acquisition and data analysis. We first recruited subjects which was
followed by comprehensive tests to screen them for eligibility. This is followed by hyperinsulinemic-euglycemic clamp, procedure to measure insulin sensitivity and muscle
biopsies are collected. The study was performed in the following order: biopsy homogenization; immunoprecipitation of the “bait” protein (PP2Ac), at the endogenous level;
followed by one dimensional SDS-PAGE to separate co-interaction proteins; in-gel
trypsin digestion to generate peptide fragments; and HPLC-ESI-MS/MS analysis to
identify co-immunoprecipitating proteins. Multiple biological comparisons and immunoprecipitation of NIgG (as non-specific control) were used for false positive minimization. Extensive literature searches as well as bioinformatics were used to integrate
clinical and proteomics data and to identify pathways and functional categories in
which identified PP2Ac interaction partners were involved.

2.1 MATERIALS
2.1.1 REAGENTS
Reagents are from these suppliers: sequencing-grade modified trypsin
(Promega, Madison, WI); protein A sepharose and iodoacetamide (Sigma, St Louis,
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MO); C18 ZipTip (Millipore, Billerica, MA); antibody to PP2Ac (Upstate/Millipore,
Billerica, MA).
2.1.2 SUBJECTS
A total of 8 overweight/obese non-diabetic volunteers were recruited and took
part in the study at the C. S. MOTT Clinical Research Center at Wayne State University.
Written consent was attained from all participants and the study was explained in detail
including the indirect benefits and risks. No one had any significant medical problems,
and none engaged in any heavy exercise, and they were directed to stop all kinds of
exercise for at least 2 days prior to the study. Institutional Review Board of Wayne
State University approved this protocol.
2.1.3 HYPERINSULINEMIC-EUGLYCEMIC CLAMP WITH MUSCLE BIOPSIES
A hyperinsulinemic-euglycemic clamp was used to assess insulin sensitivity
and expose skeletal muscle to insulin in vivo, as previously described31. Followed by a
ten hour overnight fast, the study began at approximately 08:30 hours (time -60
min).Two catheters were placed, one in an antecubital vein, maintained throughout the
study for infusions of insulin and glucose. The second in a vein in the contra lateral
arm, which was covered with a heating pad (60°C). The purpose of heating pad is to
arterialize the venous blood being collected. Blood samples were collected for determination of plasma glucose concentrations. At approximately 09:00 hours (time −30 min),
under local anesthesia, a percutaneous needle biopsy of the vastus lateralis muscle was
performed. These biopsy samples were blotted free of blood, cleaned of connective
tissue and fat (~30 sec), and then frozen in liquid nitrogen. At 09:30 hours (time 0 min),
continuous human insulin (Humulin R; Eli Lilly, Indianapolis, IN) infusion was begun
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at a rate of 80 mU m-2 minute-1, and continued for 120 min. Plasma glucose was measured at 5-min intervals throughout the clamp. Euglycemia was maintained at 90 mg/dl
by variable infusion of 20% d-glucose. Another biopsy is taken at 11:30 hours (time
120 minutes) in the contralateral leg.
Plasma insulin concentration was calculated using the ALPCO Insulin ELISA
Jumbo (Alpco Diagnostics, Salem, NH).

2.2 PROTEOMICS SAMPLE PREPARATION AND ANALYSIS
2.2.1 SAMPLE PREPARATION
Biopsies were homogenized and processed as described31-33. The lysate proteins were precleared with NIgG followed by PP2AC immunoprecipitation. The coimmunoprecipitates were resolved on one dimensional SDS-PAGE, which is followed
by in-gel trypsin digestion, peptide enrichment, and HPLC-ESI-MS/MS analysis using
a LTQ-Orbitrap Elite as described31. Peptides/protein identification and quantification
were performed using the MaxQuant software. It is one of the most prevalent quantitative proteomics software34. Using this, peak areas for each protein were obtained by
selecting the option for label-free quantification (LFQ). Only those proteins with a minimum of 2 unique peptides and with false discovery rate (FDR) at 0.01 were considered.
In total, 2057 proteins were identified in the 16 muscle biopsies using HPLC-ESIMS/MS.
To be considered as a PP2Ac interaction partner, a protein has to additionally
pass these following criteria: 1). with an enrichment ratio >10; 2). Identified with LFQ
peak area (PA) in more than half of the PP2Ac IP (i.e. >8 biopsies used). The enrichment ratio was calculated as follows: 1st, PA for a protein identified in a gel lane was
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normalized against the sum of the peak areas for all proteins identified in the same gel
lane to obtain normalized ratio for individual protein, Norm:i,
Norm: 𝑖 =

PA𝑖
∑n1 PA𝑖

Then, the average of normalized ratio for each protein in the IRS1 co-immunoprecipitates, Average_Norm:i_IRS1, as well as the average of normalized ratio for the
same protein in the NIgG co-immunoprecipitates, Average_Norm:i_NIgG, were obtained. Finally, Average_Norm:i_PP2Ac was divided by Average_Norm:i_NIgG,
which gives the enrichment ratio for each protein.
Enrichment_Ratio: 𝑖 =

Average_Norm: 𝑖_PP2Ac
Average_Norm: 𝑖_NIgG

Proteins exclusively detected in the PP2Ac immunoprecipitates were identified
as we used NIgG as a control. Nevertheless, this will give rise to false negatives. But
due to the high sensitivity of our method, trace amounts of a protein will be detected
even it was non-specifically absorbed on the NIgG beads, it may be identified with
minimum 2 unique peptides with FDR at 0.01. However, if a protein is true component
of the PP2Ac complex, higher peak area will be assigned to this protein in the PP2Ac
sample than in the NIgG sample.
To determine the relative quantities of PP2Ac interaction partners in human
skeletal muscle biopsies before and after insulin infusion in vivo, the PA for each protein identified in a specific biopsy was normalized against the PA for PP2Ac identified
in the same biopsy, which results in Norm:j.
Norm: 𝑗 =

PA𝑗
PA_PP2Ac

The normalization strategy is widely used in proteomics studies involving protein-protein interactions35, and uses similar concept as in western blotting, where the
signal for an interaction protein is normalized against that for the protein serving as the
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“bait.” The normalized peak area for each PP2Ac interaction partner, Norm:j, was converted to log2 form and compared within the group to assess effects of insulin on protein-protein interactions involving PP2Ac.
2.2.2 STATISTICAL ANALYSIS
Although a large number of proteins were assigned in at least one of 16 biopsies that were studied, various filters narrowed the number of proteins that were used
in comparisons among groups as described above. This approach is diagrammed in
Fig. 5. To assess the effects of insulin within group, statistical significance was calculated applying paired t tests. Changes were statistically significant at p<0.05.
Pathway analysis on PP2Ac interaction partners was performed using Ingenuity
Pathway Analysis (Ingenuity Systems, Inc., Redwood City, CA), which is widely used
and contain biological and chemical interactions and functional annotations created by
manual curation of the scientific literature36. A pathway was considered significantly
enriched if the p-value for that pathway was less than 0.01 and contained at least 4
identified PP2Ac partners.
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CHAPTER 3 RESULTS
Clinical characteristics of the eight overweight/obese control subjects. Table 4
lists the clinical characteristics for the subjects.

3.1 PP2AC INTERACTION PARTNERS IN SKELETAL MUSCLE FROM
OVERWEIGHT/OBESE HUMAN PARTICIPANTS
PP2Acα and PP2Acβ were detected in PP2Ac immunoprecipitates from all 16
biopsies used for the study, but were not detected at all in the NIgG immunoprecipitates.
In total, 186 proteins met the criteria for classification as PP2Ac interaction partners
(Figure 5 and Table 4). Note that PP2Ac interaction partners listed in Table 5 may involve both direct and indirect partners.
Table 4 lists the 186 PP2Ac interaction partners with fold changes between biopsies obtained before and after insulin infusion in overweight/obese human participants. Among these 186 PP2Ac interaction partners, 14 partners were previously reported while 172 were novel. The known PP2Ac interaction partners included AMPK,
CCT2, CCT3, CCT4, CCT5, CCT6A, CCT8, IGBP1, PPME1, PPP2R1A, PPP2R2A,
Rpn2, TCP1, TUBA8.
Ingenuity pathway analysis on the 186 PP2Ac interaction partners and PP2Ac
suggested various pathways significantly enriched compared to the whole genome
background, such as mTOR and MAPK signaling (Figure 6 and Table 5). One of the
significantly enriched pathway, mTOR signaling, was illustrated in Figure 7
We also performed network analysis using Ingenuity pathway analysis for the
186 PP2Ac interaction partners and PP2Ac to illustrate how these partners can be interrelated. Figure 6 shows the network with the highest score and highest number of
interaction partners identified in this study.

18

3.2 INSULIN-RESPONSIVE PP2AC INTERACTION PARTNERS IN SKELETAL MUSCLE FROM OVERWEIGHT/OBESE HUMAN PARTICIPANTS

Upon insulin infusion in vivo, 17 PP2Ac interaction partners showed significant
difference in their association with PP2Ac (P<0.05). Among them, ten PP2Ac interaction partners showed decreased interaction (Table 6) and the remaining seven showed
increased interaction (Table 7).
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CHAPTER 4 DISCUSSION
4.1 PP2AC INTERACTION PARTNERS IN SKELETAL MUSCLE FROM
OVERWEIGHT/OBESE HUMAN PARTICIPANTS

Using the proteomics approach for protein-protein interactions developed in our
laboratory31, we have identified 186 PP2Ac interaction partners in skeletal muscle form
8 overweight/obese human participants, which represents the largest PP2Ac interaction
network in humans to date. Among them, 14 were known PP2Ac interaction partners
while 172 were novel (Table 4).
Among these 14 PP2Ac interaction partners, PPP2R1A and PPP2R2A are ‘A’ subunit alpha isoform and ‘B’ subunit alpha isoform of the PP2A complex, respectively.
PPME1 is protein methylesterase, which catalyzes the demethylation of PP2A on leucine309. As mentioned in the Introduction, demethylation of the catalytic subunit at
this site may decrease the stability of the PP2Ac complex and subsequent PP2A activity. When PP2Ac is not exit as a complex, it will be directed for proteasome degradation
by the E3 ubiquitin ligase. IGBP1 also known as alpha4, binds to catalytic subunit
thereby stabilizing and preventing it from the degradation37. CCT2, CCT3, CCT4,
CCT5, CCT6A, CCT8, TCP1 are chaperone proteins. All the translated proteins need
to be folded properly in order to achieve the tertiary structure. Sometimes, they can be
misfolded. These misfolded or unfolded proteins can aggregate to form lethal complexes. The function of these chaperones is to correct the partially folded or misfolded
proteins using ATP as source of energy38. Rpn2 is Ribophorin II, which is subunit of
the enzyme oligosaccharyltransferase complex. This enzyme transfers glycosyl group
from a lipid molecule to asparagine of Asn-x-Thr/Ser sequence. The enzyme is specific
to the membrane of Rough endoplasmic reticulum. Glycosylation is a post translational
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modification of the proteins. This modification of nascent proteins is important sometimes in the proper folding of the proteins39. TUBA8 belongs to alpha tubulin protein
family that heterodimerizes and forms microtubule40. AMPK is a protein kinase which
is activated in response to altered energy levels in the cell. PP2A has been shown to be
able to dephosphorylate AMPK41. Higher ATP levels reduce the activity of AMPK.
When the AMP levels rise, ATP is exchanged for AMP and this activates AMPK.
AMPK comprises of alpha beta and gamma subunits. Alpha and beta having two
isoforms and gamma subunit with three isoforms. Identified isoforms are PRKAG1
(gamma 1), PRKAA2 (alpha 2), PRKAB2 (beta 2). PRKAG1 is ubiquitously expressed
whereas PRKAA2 and PRKAB2 are found abundant in skeletal muscle cells. It is
known to have important role in skeletal muscle insulin sensitivity42. In skeletal muscle,
activation of AMPK will cause fatty acid and glucose oxidation. It also plays a role in
activation of GLUT4 transporters which are responsible for uptake of glucose upon
recruitment to plasma membrane. Plays a role in glycogen metabolism43. Activation is
carried out by phosphorylation of AMPK at various serine and threonine sites. It is
phosphorylated by minimum three kinases. Its binding to PP2Ac may change the phosphorylation status of this kinase and thereby its activation or inactivation. Since denovo
AMP synthesis will activate AMPK, experiments were conducted using rat hepatocytes
to see if altering the activity of enzymes involved in purine biosynthesis will improve
insulin sensitivity. They found that abundant adenosuccinate lyase (ADSL) can lead to
increased AMP production. There by AMPK activation and improved insulin sensitivity44. Both ADSL and AMPK are found as potential interaction partners.
mTOR pathway has great impact on the cell growth and metabolism. It regulates
protein biosynthesis, lipid synthesis, mitochondrial biogenesis and metabolism. Previous reports show that PP2A is down regulated by mTOR, and degradation of IRS1 by
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mTOR is achieved through inhibition of PP2A45. In the present work, we detected transcription factors (elf3 and elf4G) that regulate protein synthesis as partners of PP2Ac.
Growth factors like insulin stimulate mTOR by increased phosphorylation of TSC2
protein by kinases like PKB, ERK1/2 and RSK1. This TSC2 phosphorylation leads to
inactivation of TSC1/2 and there by activation of Mtor. AMPK is activated in response
to low energy levels. This activated AMPK phosphorylates and reduce the activity of
TSC2 and thereby reduce mTOR activation46. RSK1 and AMPK regulate the mTOR
pathway mainly by phosphorylation events by kinases and dephosphorylation events
possibly regulated by PP2A.

4.2 INSULIN-RESPONSIVE PP2AC INTERACTION PARTNERS IN SKELETAL MUSCLE FROM OVERWEIGHT/OBESE HUMAN PARTICIPANTS

Upon insulin infusion in vivo, 10 PP2Ac interaction partners had a decreased association with PP2Ac (P<0.05, Table 6). Among them, 5 were involved in vesicle traffic,
including Archain1, Adp-ribosylation factor 4, Coatomer protein complex

subunit alpha, Sec1 family domain containing 1, Vesicle amine transport 1.
Archain1, also known as coatomer protein complex subunit delta, and COPA, which is
coatomer protein complex subunit alpha, are coat proteins. They have important function in transporting proteins between Golgi apparatus and Endoplasmic reticulum. They
are also involved in budding of the vesicles from the Golgi membrane. These coat proteins require ARF proteins for this function47. ARF proteins are GTP-binding proteins
which upon activation at the membrane recruit these coat proteins and thereby aiding
these vesicles to bud from Golgi apparatus48. ARF4 is involved in insulin mediated
activation of Phospholipase D and also Vesicle trafficking. SCFD1, Sec1 family domain containing 1, is also involved in vesicle transport between Golgi and Endoplasmic
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reticulum. VAT1, vesicle amine transport 1, is found to be involved in regulation of
mitochondrial fusion. It is shown to have ATPase activity.
Glycogenin is a primer for the glycogen synthesis which is further extended by glycogen synthase and glycogen branching enzyme49.
Proteasome 26S subunit, ATPase, 3 is part of the proteasome complex which degrades proteins that are tagged with ubiquitin50. Ubiquitin proteasome plays an important role in regulation of Insulin signaling pathway by ubiquitination and subsequent
degradation of Insulin Receptor Substrate, GLUT1 and GLUT451.
STAT3 is a transcription factor which upon activation by any growth factor will
cause transcription of appropriate genes. It was showed that phosphorylated STAT3
amounts are increased by two fold in overweight T2D compared to overweight controls.
STAT3 is also shown to contribute to insulin resistance in various tissues like liver and
smooth muscle52.
Upon insulin infusion in vivo, 7 PP2Ac interaction partners had an increased
association with PP2Ac (P<0.05, Table 6). ATP synthase beta polypeptide and dihydrolipogenase are mitochondrial proteins. ATP synthase beta is one of the subunits of
the catalytic core of ATP synthase enzyme. This enzyme catalyzes the formation of
ATP from ADP in the mitochondria53. Mitochondrial dysfunction is linked to obesity
and Type II Diabetes. Experiments were conducted on human skeletal muscle comparing the phosphorylation of this protein between basal and insulin stimulated biopsies of
lean, obese and T2D. The amount of ATP synthase in basal biopsies is found to be
decreased in obese and T2D compared to lean. They found abnormal phosphorylation
sites in obese and T2D54. As a partner of PP2Ac, It is possible that phosphorylation and
dephosphorylation of this protein is regulated by PP2A which thereby influences Insulin signaling and insulin resistance.
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PGM1, phosphoglucomutase-1, is involved in the breakdown and formation of glucose, Conversion of glucose 6 phosphate to glucose 1 phosphate and vice versa55.
NT5C3, 5’ Nucleotidase, breaks down nucleotides to nucleosides and phosphate.
ADSL, Adenylsuccinate lyase, catalyzes two steps in de novo Adenosine Mono
Phosphate synthesis.
PPP1R7 is a regulatory subunit of protein phosphatase 1 (PP1). PP1 also belongs to
phosphoprotein phosphatase family, and is also a serine/threonine protein phosphatase56.
PPP2R2A is one of the regulatory subunits of PP2A. Binding of this subunit catalyzed many dephosphorylation events involved in cell cycle regulation57, DNA repair58,
TGFβ signaling59, Wnt signaling60 and diseases like cancer. In islet β cells, presence of
this subunit directed PP2A to dephosphorylate FOXO1 under oxidative stress conditions61. Considering the role of regulatory subunits in regulating the localization and
specificity of PP2A, unveiling its role in skeletal muscle may reveal important information in specific to skeletal muscle.

4.3 SUMMARY
In the present work, PP2Ac was found to interact with 186 protein partners
either directly or indirectly in human skeletal muscle. This is the largest PP2Ac
interaction partner network found in humans till date. Moreover, seventeen insulinresponsive PP2Ac interaction partners in skeletal muscle were identified in
overweeight/obesse human subjects. Validating some of the important partners
(partners that may directly or indirectly effect the insulin signaling pathway) would be
the next step. In addition, comparison with lean and T2D participants will discover the
differences in the PP2Ac partners among the 3 groups. This information will help us
understand the role of PP2A in the development of inuslin resistance and T2D.

24

Figure 1. Insulin signaling pathway showing the signaling molecules involved
and various effects seen62
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B/B’/B’’/B’’’
A
C

Figure 2. Diagrammatic representation of heterotrimeric PP2A complex
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Figure 3. Main steps in mass spectrometry-based proteomics studies
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Subject recruitment
(e.g., advertisement, phone screening, scheduling, etc.)

Comprehensive screening tests
(e.g., OGTT, blood chemistry, BMI, ECG, etc.)

In-patient clinical testing
(e.g., muscle biopsies, hyperinsulinemic-euglycemic clamp)

Muscle biopsies from overweight/obese (n=7): Basal & 2h
16 biopsies

5-10mg protein lysate
NIgG Co-IP & PP2Ac Co-IP

1D-SDS-PAGE
Trypsin in-gel digestion

HPLC-ESI-MS/MS
LTQ-Orbitrap Elite

MaxQuant: Protein identification & quantification
Ingenuity: Pathway & network analysis

Figure 4. Clinical and proteomics data acquisition and data analysis
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Proteins identified with minimum 2 unique peptides with FDR at 0.01 in at least one
PP2Ac IP after excluding common contaminants?
(2057 proteins, including
PPP2CA/B)
Enrichment ratio for each protein determined. Enrichment ratio for a protein >
10 (PP2Ac vs NIgG IP)?
(586 proteins, including PPP2CA/B)
Identified with LFQ peak area (PA) in more than half (e.g., > 8 out of 16) PP2Ac
IP samples?
(188 proteins, including PPP2CA/B)
Normalized PA for PP2Ac interaction partners determined

With a fold change over basal greater than 1.5 (i.e., 1.5 fold increase) or
less than 0.67 (i.e., 1.5 fold decrease) Insulin vs. Basal?
(115 proteins)

P<0.05 by paired t tests?
(17 proteins)

Figure 5. Proteomics data analysis
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PPARα/RXRα Activation

8

ERK/MAPK Signaling

12

Protein Kinase A Signaling

8

Regulation of eIF4 and p70S6K Signaling

11

Protein Ubiquitination Pathway

9

AMPK Signaling

11

mTOR Signaling

5

Epithelial Adherens Junction Signaling

12
0

2

4

6

-log p value

Figure 6. Significantly enriched pathways for the 186 PP2Ac interaction partners
and PP2Ac in human skeletal muscle. The number of PP2Ac interaction partners
identified in this study in a particular pathway is beside the bar.
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Figure 7. The significantly enriched pathway, mTOR signaling, for the 186
PP2Ac interaction partners and PP2Ac. PP2Ac interaction partners were
highlighted in yellow and PP2A was highlighted in purple
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Figure 8. Network pathway obtained from Ingenuity Pathway Analysis Pathway
obtained using 70 molecules per network and the one assigned with highest score
is taken; shows 45 interaction partners; target protein PP2Ac (in purple) proteins
without any change (in yellow), which showed significant decrease (in red) and
significant increase (in green) upon insulin stimulation
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Table 1 showing the various isoforms of PP2A subunits, their cellular and subcellular distribution8. HE: high expression
Subunit

Gene

Iso-

Other name

form
Scaffold (A)

PPP2R1A

Α

Normal

tissue Subcellular

distribution

distribution

PR65α,

Ubiquitously ex- Cytosol

PP2A-Aα

pressed

and

highly expressed
in ovary (oogenesis)
PPP2R1B

Β

PR65β, PP2A- Ubiquitously ex- Cytosol
Aβ

pressed

and

highly expressed
in ovary (oogenesis)
Catalytic (C)

PPP2CA

Α

PP2Acα

Brain and heart Cytoplasm
(HE). Present in and nucleus
skeletal muscle21

PPP2CB

Β

PP2Acβ

Brain and heart Cytoplasm
(HE)

Regulatory
(B)

PPP2R2A

Α

and nucleus

PR55α,

Widely

PP2ABα

uted in all tissues

distrib- Membranes,
cytoplasm,
microtubules
nucleus.
Golgi

com-
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plex,

endo-

plasmic reticulum

and

neurofilaments
PPP2R2B

PPP2R2C

Β

Γ

PR55β,

Brain and testis Cytosol

PP2ABβ

(HE)

PR55γ,

Brain (SE)

Mainly

PP2ABγ

in

Cytoskeletal
fraction

PPP2R2D

Δ

PR55δ,

Wide spread dis- Cytosol

PP2ABδ

tribution in tissues, Testis (HE)

Regulatory

PPP2R5A

Α

(B′)

PR56/61α,

Cardiac

PP2AB′α

and skeletal mus-

tissues Cytoplasm

cles63 (HE)
PPP2R5B

Β

PR56/61β,

Brain (HE)

Cytoplasm

PP2AB′β
PPP2R5C

Γ1, 2,3 PR56/61γ,
PP2AB′γ

Cardiac

tissues Cytoplasm

and skeletal mus- and nucleus
cles64 (HE)

PPP2R5D

Δ

PR56/61δ,

Primarily exist in Cytoplasm,

PP2AB′δ

brain

nucleus, mitochondria,
microsomes
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PPP2R5E

Regulatory

PPP2R3A

Ε

Α

PR56/61ε,

Primarily exist in Cytoplasm

PP2AB′ε

brain

PR130, B″α1

Brain (HE), heart, Centrosome

(B″)

lung, kidney and and
muscle65
PPP2R3A

Α

PR72, B″α2

complex

Heart (HE) and Cytosol and
skeletal muscle65

PPP2R3B

Β

Golgi

PR70, PR48, Placenta

nucleus
Nucleus

B″β
PPP2R3C

Γ

G5PR, G4-1

During
mental

develop- Nucleus
process

expressed in fetal
brain
PPP2R3D

Δ

PR59, B″δ

Cardiac

tissue, Nucleus

kidney and lungs
Regulatory

STRN

(B″′)

Striatin,

Brain

PR110

Membrane
and

cyto-

plasm
STRN3

SG2NA

Neurons

Nucleus

PPP2R4

PTPA, PR53

Widely expressed

Cytosol, nucleus
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Table 2 showing various inhibitors of PP2A including their sources and specificity
to different phosphatases 6.
Inhibitor

Source

Inhibitory

potency

Okadaic acid

Dinoflagellates

PP2A ∼ PP4 > PP1 ∼
PP5 >>> PP2B∗

Dinophysistoxin-1

Dinoflagellates

PP2A > PP1 >>> PP2B

Microcystins

Cyanobacteria

PP2A ∼ PP1 >>> PP2B

Nodularins/Motuporin

Cyanobacteria

PP2A ∼ PP1 >>> PP2B

Calyculin A

Isolated from marine sponges

PP2A > PP1 >>> PP2B

Tautomycin

Streptomyces spiroventricilla- PP1 > PP2A >>> PP2B
tus

Cantharidin

Blister beetles

PP2A > PP1 >>> PP2B

Endothall

Synthetic compound

PP2A > PP1 >>> PP2B

Fostriecin

Streptomyces

pul- PP2A ∼ PP4∗

veraceussubsp. Fostreus
TF-23A

Isolated from marine red alga

PP2A

Cytostatin

Streptomyces sp. MJ654-NF4

PP2A

I1PP2A

Cellular inhibitor

PP2A

I2PP2A (SET, PHAP-II,

Cellular inhibitor

PP2A

TAF-1β)
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Table 3. Clinical characteristics for the 8 overweight/obese participants in the
PP2Ac interaction partner study. Results were shown as mean ± SEM.
Gender (M/F)

(4/4)

Age (years)

42.0 ± 3.0

2

BMI (kg/m )

31.3 ± 01.3

2h OGTT Glucose (mg/dl)

115.2 ± 7.8

HBA1c (%)

5.5 ± 0.1

Fasting plasma glucose (mg/dl)

92.1 ± 3.5

Fasting plasma insulin (pmol/l)

29.0 ± 5.1

M-value (mg/kg/min)

5.8 ± 0.6
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Table 4. The 186 proteins/ protein groups met the 2 rigorous criteria (See Methods
for details) for classification as PP2Ac interaction partners in human skeletal muscle. # indicating previously identified PP2A partners.
ABHD14B

Abhydrolase domain containing 14B

ACAD8

Acyl-coa dehydrogenase family, member 8

ACADM

Acyl-coa dehydrogenase, C-4 to C-12 straight chain

ACADS

Acyl-coa dehydrogenase, C-2 to C-3 short chain

ACADSB

Acyl-coa dehydrogenase, short/branched chain

ACOT9

Acyl-coa thioesterase 9

ACP1

Acid phosphatase 1, soluble

ACTR1B

ARP1 Actin-related protein 1 homolog B, centractin beta (yeast)

ADPRHL1

ADP-ribosylhydrolase like 1

ADSL

Adenylosuccinate lyase

ADSSL1

Adenylosuccinate synthase like 1

ALDH6A1

Aldehyde dehydrogenase 6 family, member A1

ANKRD2

Ankyrin repeat domain 2 (stretch responsive muscle)

APOL2

Apolipoprotein L, 2

ARCN1

Archain 1

ARF4

ADP-ribosylation factor 4

ART3

ADP-ribosyltransferase 3

ASNA1

ArsA Arsenite transporter, ATP-binding, homolog 1 (bacterial)

ATP5A1

ATP synthase, H+ transporting, mitochondrial F1 complex, alpha
subunit 1, cardiac muscle
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ATP5B

ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide

ATP6V1B2

ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B2

ATP6V1E1

ATPase, H+ transporting, lysosomal 31kDa, V1 subunit E1

BZW2

Basic leucine zipper and W2 domains 2

CAMK2D

Calcium/calmodulin-dependent protein kinase II delta

CAMK2G

Calcium/calmodulin-dependent protein kinase II gamma

CARM1

Coactivator-associated arginine methyltransferase 1

CCDC6

Coiled-coil domain containing 6

CCT2#

Chaperonin containing TCP1, subunit 2 (beta)

CCT3#

Chaperonin containing TCP1, subunit 3 (gamma)

CCT4#

Chaperonin containing TCP1, subunit 4 (delta)

CCT5#

Chaperonin containing TCP1, subunit 5 (epsilon)

CCT6A#

Chaperonin containing TCP1, subunit 6A (zeta 1)

CCT8#

Chaperonin containing TCP1, subunit 8 (theta)

CD59

CD59 molecule, complement regulatory protein

CDC37

Cell division cycle 37

CECR5

Cat eye syndrome chromosome region, candidate 5

CKM

Creatine kinase, muscle

CKMT2

Creatine kinase, mitochondrial 2 (sarcomeric)

COPA

Coatomer protein complex, subunit alpha

COPS3

COP9 signalosome subunit 3

COQ9

Coenzyme Q9

CRBN

Cereblon
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CRYM

Crystallin, mu

CS

Citrate synthase

CUL2

Cullin 2

DARS

Aspartyl-trna synthetase

DCTN2

Dynactin 2 (p50)

DDX3X

DEAD (Asp-Glu-Ala-Asp) box helicase 3, X-linked

DDX3Y

DEAD (Asp-Glu-Ala-Asp) box helicase 3, Y-linked

DDX6

DEAD (Asp-Glu-Ala-Asp) box helicase 6

DHRS7B

Dehydrogenase/reductase (SDR family) member 7B

DIABLO

Diablo, IAP-binding mitochondrial protein

DLD

Dihydrolipoamide dehydrogenase

DLST

Dihydrolipoamide S-succinyltransferase (E2 component of 2-oxoglutarate complex)

DNAJA2

Dnaj (Hsp40) homolog, subfamily A, member 2

DNAJC7

Dnaj (Hsp40) homolog, subfamily C, member 7

DNM2

Dynamin 2

DPYSL3

Dihydropyrimidinase-like 3

EARS2

Glutamyl-trna synthetase 2, mitochondrial

ECHS1

Enoyl coa hydratase, short chain, 1, mitochondrial

EHD2

EH-domain containing 2

EIF2S3

Eukaryotic translation initiation factor 2, subunit 3 gamma, 52kda

EIF3J

Eukaryotic translation initiation factor 3, subunit J

EIF3L

Eukaryotic translation initiation factor 3, subunit L

EIF4G1

Eukaryotic translation initiation factor 4 gamma, 1
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ENDOD1

Endonuclease domain containing 1

FAHD1

Fumarylacetoacetate hydrolase domain containing 1

FGB

Fibrinogen beta chain

FH

Fumarate hydratase

FLNB

Filamin b, beta

GCDH

Glutaryl-coa dehydrogenase

GDI2

GDP dissociation inhibitor 2

GFPT1

Glutamine--fructose-6-phosphate transaminase 1

GMPPB

GDP-mannose pyrophosphorylase B

GPD1L

Glycerol-3-phosphate dehydrogenase 1-like

GPT2

Glutamic pyruvate transaminase (alanine aminotransferase) 2

GYG1

Glycogenin 1

HAGH

Hydroxyacylglutathione hydrolase

HSD17B4

Hydroxysteroid (17-beta) dehydrogenase 4

HSD17B8

Hydroxysteroid (17-beta) dehydrogenase 8

HSP90AB1

Heat shock protein 90kda alpha (cytosolic), class B member 1

IARS2

Isoleucyl-trna synthetase 2, mitochondrial

IDH3B

Isocitrate dehydrogenase 3 (NAD+) beta

IGBP1#

Immunoglobulin (CD79A) binding protein 1

KLC4

Kinesin light chain 4

KLHL31

Kelch-like family member 31

KLHL40

Kelch-like family member 40

KPNA1

Karyopherin alpha 1 (importin alpha 5)

KPNA3

Karyopherin alpha 3 (importin alpha 4)
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KPNA4

Karyopherin alpha 4 (importin alpha 3)

LDHD

Lactate dehydrogenase D

LMCD1

LIM and cysteine-rich domains 1

LYPLAL1

Lysophospholipase-like 1

MAML3

Mastermind-like 3 (Drosophila)

MAOB

Monoamine oxidase B

MAP2K6

Mitogen-activated protein kinase 6

MAPRE2

Microtubule-associated protein, RP/EB family, member 2

MURC

Muscle-related coiled-coil protein

MYH11

Myosin, heavy chain 11, smooth muscle

MYL10

Myosin, light chain 10, regulatory

MYL2

Myosin, light chain 2, regulatory, cardiac, slow

MYL6

Myosin, light chain 6, alkali, smooth muscle and non-muscle

MYL6B

Myosin, light chain 6B, alkali, smooth muscle and non-muscle

NAMPT

Nicotinamide phosphoribosyltransferase

NAP1L4

Nucleosome assembly protein 1-like 4

NDRG2

NDRG family member 2

NDUFS8

NADH dehydrogenase (ubiquinone) Fe-S protein 8, 23kDa (NADHcoenzyme Q reductase)

NEK7

NIMA-related kinase 7

NOL3

Nucleolar protein 3 (apoptosis repressor with CARD domain)

NT5C3A

5'-nucleotidase, cytosolic IIIA

P4HB

Prolyl 4-hydroxylase, beta polypeptide

PACSIN3

Protein kinase C and casein kinase substrate in neurons 3
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PCBP2

Poly(rc) binding protein 2

PCBP3

Poly(rc) binding protein 3

PCTP

Phosphatidylcholine transfer protein

PCYOX1

Prenylcysteine oxidase 1

PDHA1

Pyruvate dehydrogenase (lipoamide) alpha 1

PDHX

Pyruvate dehydrogenase complex, component X

PDIA6

Protein disulfide isomerase family A, member 6

PDK2

Pyruvate dehydrogenase kinase, isozyme 2

PGK1

Phosphoglycerate kinase 1

PGM1

Phosphoglucomutase 1

PLIN2

Perilipin 2

PPME1#

Protein phosphatase methylesterase 1

PPP1R7

Protein phosphatase 1, regulatory subunit 7

PPP2CA

Protein phosphatase 2, catalytic subunit, alpha isozyme

PPP2CB

Protein phosphatase 2, catalytic subunit, beta isozyme

PPP2R1A#

Protein phosphatase 2, regulatory subunit A, alpha

PPP2R2A#

Protein phosphatase 2, regulatory subunit B, alpha

PPP3CB

Protein phosphatase 3, catalytic subunit, beta isozyme

PPP4C

Protein phosphatase 4, catalytic subunit

PPP4R2

Protein phosphatase 4, regulatory subunit 2

PRKAA2#

Protein kinase, AMP-activated, alpha 2 catalytic subunit

PRKAB2#

Protein kinase, AMP-activated, beta 2 non-catalytic subunit

PRKAG1#

Protein kinase, AMP-activated, gamma 1 non-catalytic subunit

PRKAR1A

Protein kinase, cAMP-dependent, regulatory, type I, alpha
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PSMA4&6

Proteasome (prosome, macropain) subunit, alpha type, 4 and 6

PSMA6

Proteasome (prosome, macropain) subunit, alpha type, 6

PSMB3;6

Proteasome (prosome, macropain) subunit, beta type, 3;6

PSMC3;5

Proteasome (prosome, macropain) 26S subunit, atpase, 3;5

PSMD11

Proteasome (prosome, macropain) 26S subunit, non-atpase, 11

PTGR1

Prostaglandin reductase 1

RAB14

RAB14, member RAS oncogene family

RAB1B

RAB1B, member RAS oncogene family

RAB6A

RAB6A, member RAS oncogene family

RAB6B

RAB6B, member RAS oncogene family

RDH13

Retinol dehydrogenase 13 (all-trans/9-cis)

REEP5

Receptor accessory protein 5

RNH1

Ribonuclease/angiogenin inhibitor 1

RPL11

Ribosomal protein L11

RPN2#

Ribophorin II

RPS6KA3

Ribosomal protein S6 kinase, 90kda, polypeptide 3

RRAGA

Ras-related GTP binding A

RRAGB

Ras-related GTP binding B

RRM2B

Ribonucleotide reductase M2 B (TP53 inducible)

RTN3

Reticulon 3

SCFD1

Sec1 family domain containing 1

SCPEP1

Serine carboxypeptidase 1

SH3GLB1

SH3-domain GRB2-like endophilin B1

SMTNL2

Smoothelin-like 2
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SMYD1

SET and MYND domain containing 1

SSBP1

Single-stranded DNA binding protein 1, mitochondrial

STAC3

SH3 and cysteine rich domain 3

STARD7

StAR-related lipid transfer (START) domain containing 7

STAT3

Signal transducer and activator of transcription 3

TBRG4

Transforming growth factor beta regulator 4

TCP1#

T-complex 1

TIMM44

Translocase of inner mitochondrial membrane 44 homolog

TMEM109

Transmembrane protein 109

TMEM143

Transmembrane protein 143

TOM1

Target of myb1 (chicken)

TPM1

Tropomyosin 1 (alpha)

TRIM54

Tripartite motif containing 54

TRIM72

Tripartite motif containing 72, E3 ubiquitin protein ligase

TUBA4A;8#

Tubulin, alpha 4a;8

TUBB

Tubulin, beta class I

TUBB2A;2

Tubulin, beta 2A class iia; 2B class iib

B
TUBB4A

Tubulin, beta 4A class Iva

TUBB6

Tubulin, beta 6 class V

TUBB8

Tubulin, beta 8 class VIII

UBAC1

UBA domain containing 1

UBQLN2

Ubiquilin 2

UGP2

UDP-glucose pyrophosphorylase 2
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UQCRFS1

Ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1

USP14

Ubiquitin specific peptidase 14 (trna-guanine transglycosylase)

VAT1

Vesicle amine transport 1

VPS25

Vacuolar protein sorting 25 homolog (S. Cerevisiae)

VTA1

Vesicle (multivesicular body) trafficking 1

WARS

Tryptophanyl-trna synthetase

ZADH2

Zinc binding alcohol dehydrogenase domain containing 2
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Table 5. Significantly enriched pathways for the PP2Ac interaction partners iden-

TUBB6, TUBA8, MYL2, MYL6,
Epithelial Ad7.61

TUBB8, MYL6B, TUBB2A,

herens Junction

12
TUBA4A, TUBB4A, MYH11,

Signaling
TUBB, TUBB2B
TCA Cycle II
(Eukaryotic)

mTOR
ing

Signal-

5.68

CS, DLST, DLD, FH, IDH3B
5

PPP2CB,PPP2R1A,PRKAB2,
5.48
PPP2CA, PPP2R2A, PRKAA2,

11

RPS6KA3, EIF3J, EIF4G1, EIF3L
AMPK Signaling

PPP2CB, PPP2R1A, PRKAB2,
5.09
CKM, PPP2CA, PPP2R2A,

9

PRKAA2, PRKAG1, PRKAR1A
PSMB3+ND6:N6, PSMD11,
Protein Ubiquitination Pathway

4.3

PSMA6, USP14, HSP90AB1,
11
CUL2, PSMA4, PSMC3, PSMB6,
DNAJC7, PSMC5

study

interaction partners in the

PP2Ac

Number of identified

Gene Names

-log(p-value)

ways

Ingenuity Canonical Path-

tified in the study revealed by Ingenuity Pathways Analysis.
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Regulation of
eIF4
and
p70S6K Signaling

PPP2CB, PPP2R1A, PPP2CA,
3.93
PPP2R2A, EIF2S3, EIF3J,

8

EIF4G1, EIF3L
FLNB, MYL10, CAMK2D,
Protein Kinase
A Signaling

3.35

PPP3CB, MYL2, MYL6, PPP1R7,
12
MYL6B, ACP1, PRKAG1,
PRKAR1A, CAMK2G

PPARα/RXRα
Activation

2.07

MAP2K6, PRKAB2, HSP90AB1,
6
PRKAA2, PRKAG1, PRKAR1A
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Table 6. Interaction partners that showed significant difference (decreased) upon
insulin stimulation

Gene

Protein

Function

name
ARCN1

Archain1 (Coatomer Protein Complex, Vesicle traffic
Subunit Delta)

ARF4

Adp-ribosylation factor 4

Vesicular trafficking and activators of
phospholipase D

COPA

Coatomer protein complex, subunit al- Vesicle traffic
pha

GYG1

Glycogenin 2

Primer for glycogen synthesis

PSMC3

Proteasome (prosome, macropain) 26S Degradation of proteins
subunit, atpase, 3

RPL11

Ribosomal protein L11

rRNA maturation and formation of
the 60S ribosomal subunits

SCFD1

Sec1 family domain containing 1

Vesicular transport between the endo-

plasmic reticulum and the Golgi
STAT3

Signal transducer and activator of tran- Transcription factor
scription 3 (acute-phase response factor)

TUBB6

Tubulin, beta 6 class V

Microtubule protein

VAT1

Vesicle amine transport 1

Vesicle transporter
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Table 7. Interaction partners that showed significant difference (increased) upon
insulin stimulation:
Gene name

Protein

Function
Catalyzes steps in denovo AMP

Adenylsuccinate lyase
synthesis

ADSL

Subunit of Mitochondrial proATP synthase, H+ transporting, mitotein ATP Synthase; production
chondrial F1 complex, beta polypeptide
of ATP

ATP5B
DLD

Dihydrolipoamide dehydrogenase

Mitochondrial enzyme

NT5C3

5'-nucleotidase, cytosolic IIIA

Breakdown of nucleotides
Glucose-1-phosphate to glucose

Phosphoglucomutase 1
6 phosphate and Vice versa

PGM1

Protein phosphatase 1, regulatory subunit Dephosphorylation of proteins
PPP1R7

7
Protein phosphatase 2, regulatory subunit Dephosphorylation of proteins

PPP2R2A

B, alpha
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ABSTRACT
NOVEL PROTEIN PHOSPHATASE 2A COMPLEXES IN SKELETAL MUSCLE
FROM OBESE INSULIN RESISTANT HUMAN SUBJECTS
by
DIVYASRI DAMACHARLA
May 2015
Advisor: Dr. Zhengping Yi
Major: Pharmaceutical Sciences (Pharmacology and Toxicology)
Degree: Master of Science

Type 2 Diabetes is a metabolic disorder associated with insulin resistance and
consequent high blood glucose levels. Maximum glucose disposal takes place in skeletal muscle and studying skeletal muscle insulin resistance is crucial. Protein Phosphatase 2A (PP2A) is one of the major serine/threonine phosphatases belonging to PhosphoProteinPhosphatase (PPP) family. It constitutes about 80% of all serine/threonine
phosphatases. It is regulated by numerous regulatory subunits as well as other substrate
molecules and post translational modifications. This alters their localization, activity
and also its target molecules. Many evidences show the effect of insulin on PP2Ac and
its abnormal regulation in conditions of glucolipotoxicity. Thus, studying PP2Ac interaction partners in respect to type 2 diabetes will give insight into its role in insulin
resistance.
Here, we studied interaction partners of PP2Ac in obese insulin resistant human
subjects. Two skeletal muscle biopsies, basal and insulin stimulated are obtained from
each individual using hyperinsulenemic euglycemic clamp technique. Using ESIHPLC-MS/MS, we identified 186 interaction partners. Out of which 14 partners were
previously identified by other groups which leaves 172 novel partners. This is the largest PP2Ac interaction network found till date. We also identified 17 insulin responsive
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PP2Ac partners. Several important PP2Ac interaction partners molecules were identified, for the 1st time, in skeletal muscle from humans. Among them,, some are known
to affect PP2Ac activity and others are significantly associated with insulin signaling.
Further validation of these partners will help with a better understanding of the role and
regulation of PP2Ac in terms of insulin resistance in obese individuals.
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